



(43) International Publication Date
3 July 2014 (03.07.2014)

(10) International Publication Number
WO 2014/105671 A1

(51) International Patent Classification:

A61K 39/02 (2006.01) *C12R 1/35* (2006.01)
A61K 39/00 (2006.01) *C12N 1/20* (2006.01)

(21) International Application Number:

PCT/US2013/076803

(22) International Filing Date:

20 December 2013 (20.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/747,026 28 December 2012 (28.12.2012) US

(71) Applicant (for all designated States except IR, SA, US):
BOEHRINGER INGELHEIM VETMEDICA GMBH
[DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein
(DE).

(72) Inventors; and

(71) Applicants : **JORDAN, Dianna M. Murphy** [US/US];
c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900
Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut
06877-0368 (US). **MARTINSON, Brian Thomas**
[US/US]; c/o VP, IP Legal, Boehringer Ingelheim USA
Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Con-
necticut 06877-0368 (US). **MUEHLENTHALER,**
Christine Margaret [US/US]; c/o VP, IP, Legal,
Boehringer Ingelheim USA Corp., 900 Ridgebury Road,
P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).
NEUBAUER, Axel [DE/US]; c/o VP, IP, Legal,
Boehringer Ingelheim USA Corp., 900 Ridgebury Rd.,
P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).
IYER, Arun V. [IN/US]; c/o VP, IP Legal, Boehringer In-

gelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368,
Ridgefield, Connecticut 06877-0368 (US).

(74) Agents: **MORRIS, Michael P.** et al.; Boehringer Ingel-
heim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box
368, Ridgefield, CT 06877-0368 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: IMMUNOGENIC COMPOSITION COMPRISING MYCOPLASMA ANTIGENS

(57) Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of *M. hyorhinis* and one or more antigens of *M. hyosynoviae*; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of *M. hyorhinis*, *M. hyopneumoniae* and *M. hyosynoviae*; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of *M. hyorhinis*, *M. hyopneumoniae* and *M. hyosynoviae* in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.



WO 2014/105671 A1